Fate Therapeutics

^{Priced, Nasdaq: FATE}

Early clinical-stage biotech developing stem cell treatments for orphan diseases.

Industry: Health Care

First Day Return: +10.3%

FATE

Early clinical-stage biotech developing stem cell treatments for orphan diseases.

IPO News for Fate Therapeutics

US IPO Recap: Twitter starts countdown to November offering, Potbelly pops 10/07/13
Fate Therapeutics prices IPO at $6, at low end of the revised range 10/01/13
Orphan disease biotech Fate Therapeutics decreases range and increases shares offered 09/30/13

IPO Data
IPO Date	09/30/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$40
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.fatetherapeutics.com
Headquarters	San Diego, CA, United States
Founded	2007
Employees at IPO	33

IPO News for Fate Therapeutics

Fate Therapeutics (FATE) Performance